معرفی
Andrew Lewis serves as a Visiting Professor in the School of Engineering and Materials Science at Queen Mary University of London while maintaining active industry leadership as R&D Director at Owen Mumford Ltd. With 30 years of industrial R&D experience across major corporations (ICI, Johnson & Johnson, Boston Scientific) and specialized medical device firms, he leads a team of 67 engineers in developing next-generation drug delivery systems.
His educational background includes a BSc and PhD, complemented by professional credentials CChem, CSi, and multiple fellowships. Lewis specializes in translating biomedical innovations from bench to bedside, with particular expertise in:
- Engineering biocompatible implant surfaces
- Modulating active agent delivery for cardiovascular and cancer therapies
- Developing integrated drug-device combination products
- Optimizing manufacturability and sterilization protocols
His work bridges critical gaps between academic research and commercial medical device development, focusing on real-world clinical implementation challenges.
Professor Lewis has received significant recognition through prestigious fellowships:
- Fellow of the Institute of Materials Minerals and Mining
- Fellow of the Academy of Pharmaceutical Sciences
- Fellow of the Royal Society of Chemistry
- Fellow of the Royal Academy of Engineers
- Royal Society Entrepreneur in Residence
- Industry Fellow designation
With over 55 patents and 240 research publications (h-index 61), he has successfully commercialized technologies across multiple companies. His current industry role involves building innovation pipelines for autoinjection devices, pen delivery systems, and blood sampling technologies while advising Owen Mumford's executive strategy.
At Queen Mary, he is restructuring the Biomaterials & Bioengineering curriculum to equip engineering graduates with industry-ready skills for medical technology careers, leveraging his extensive experience in regulatory pathways and product commercialization.
